Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07382817 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

A Phase 1 study of Neoplasms, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
33
Enrollment target
1
Study location

NCT07382817 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07382817, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell lymphoma that is relapsed or refractory. The safety and possible side effects of JV-394 will also be studied.

Conditions Studied

Neoplasms

Interventions

  • DRUG JV-394

Study Locations (1)

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2026-02-18
Est. Completion 2031-12-09
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07382817

The ClinicalTrials.gov registry entry for NCT07382817 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JV-394 is the first listed.

NCT07382817 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07382817 about?

NCT07382817 is a clinical study titled "Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms". The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell lymphoma that is relapsed or refractory. The safety and possible side effects of JV-394 will also be studied.

What is the current status of trial NCT07382817?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2026-02-18. Estimated completion is 2031-12-09.

What conditions does trial NCT07382817 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT07382817?

The interventions under investigation include: JV-394 (DRUG).

Who is sponsoring clinical trial NCT07382817?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07382817 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.